罗格列酮对慢性阻塞性肺疾病大鼠的抗炎作用

发布时间：2018-02-25 08:06

本文关键词： 慢性阻塞性肺疾病炎症 IL- MMP- MMP- TNF-α 罗格列酮　出处：《广东医学》2017年14期 　论文类型：期刊论文

【摘要】：目的研究罗格列酮对慢性阻塞性肺疾病(COPD)大鼠肺组织匀浆中白细胞介素-6(IL-6)、基质金属蛋白酶-2(MMP-2)、基质金属蛋白酶-9(MMP-9)、肿瘤坏死因子-α(TNF-α)的影响。方法采用气管内滴注脂多糖联合香烟烟熏建立COPD大鼠模型。SPF级成年雄性Wistar大鼠50只随机分为5组,对照组(A组)、模型组(B组)、罗格列酮组1(C组)、罗格列酮组2(D组)、罗格列酮组3(E组),每组10只,C组、D组、E组每天上午烟熏前分别给予罗格列酮钠片0.1、0.15、0.2 mg/kg灌胃,A组、B组给予1 m L生理盐水灌胃,30 d后观察大鼠的一般状况和体重改变。采用酶联免疫吸附法(ELISA)检测肺组织匀浆中IL-6、MMP-2、MMP-9及TNF-α含量,观察罗格列酮对COPD大鼠的抗炎作用。结果实验开始前所测的各组大鼠体重差异无统计学意义(P0.05)。实验结束时,与A组体重变化相比,B组大鼠体重增长最少,C组、D组、E组次之(P0.05)。C、D、E组三组大鼠之间体重变化差异无统计学意义(P0.05)。B组肺组织匀浆中MMP-2、TNF-α的表达均较A、C、D、E组明显升高(P0.05),C、D、E组中MMP-2、TNF-α的表达较A组升高(P0.05),较B组减低(P0.01),3组间差异无统计学意义(P0.05)。B组肺组织匀浆中MMP-9、IL-6的含量最高,A组最低,C、D、E组随着罗格列酮浓度的升高MMP-9、IL-6的含量逐渐降低,差异有统计学意义(P0.05)。结论罗格列酮对抑制肺部炎症介质的释放、基质金属蛋白酶的产生具有重要作用,可减轻气道炎症、肺实质损伤和气道重塑。罗格列酮在COPD的防治中具有一定的作用。
[Abstract]:Objective to study the effects of rosiglitazone on interleukin-6 (IL-6), matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), tumor necrosis factor- 伪 (TNF- 伪) in lung tissue homogenate of rats with chronic obstructive pulmonary disease (COPD). Establishment of COPD rat model by combination of sugar and cigarette smoke. Fifty male Wistar rats of SPF grade were randomly divided into 5 groups. Control group, model group, rosiglitazone group, rosiglitazone group, rosiglitazone group, rosiglitazone group, rosiglitazone group, rosiglitazone group and rosiglitazone group, 10 rats in each group were given rosiglitazone sodium tablets 0.10.150.2 mg/kg before smoking every morning. The general status and weight change of rats were observed after oral administration of 1 mL normal saline for 30 days. The levels of IL-6, MMP-2, MMP-9 and TNF- 伪 in lung tissue homogenate were detected by enzyme linked immunosorbent assay (Elisa). To observe the anti-inflammatory effect of rosiglitazone on COPD rats. Results there was no significant difference in body weight of each group before the beginning of the experiment. Compared with the weight change of group A, the weight gain of rats in group B was the least than that in group C, group D, group E, followed by group E, there was no significant difference in body weight change among the three groups. There was no significant difference in the expression of MMP-2 and TNF- 伪 in lung tissue homogenate of group A and B, which were significantly higher than those of group ACDE in the group of P0.05TNF- 伪, and the expression of MMP-2TNF- 伪 in the lung tissue homogenate of group B was significantly higher than that in group ACDE. The expression of MMP-2 / TNF- 伪 was higher than that of group A (P 0.05A), but there was no significant difference between group B and group B (P 0.05). The content of MMP-9 and IL-6 in lung homogenate of group A and group A decreased gradually with the increase of rosiglitazone concentration, and the level of MMP-9IL-6 in group A decreased gradually with the increase of rosiglitazone concentration. Conclusion rosiglitazone plays an important role in inhibiting the release of pulmonary inflammatory mediators and producing matrix metalloproteinases, and can reduce airway inflammation. Lung parenchyma injury and airway remodeling. Rosiglitazone plays a role in the prevention and treatment of COPD.
【作者单位】：江门市中心医院呼吸内科;
【基金】：广东省公益研究与能力建设专项课题(编号:2014A020212377)
【分类号】：R965

【相似文献】